– SWITZERLAND, Lausanne – Oculis S.A., a late-stage biopharmaceutical company focused on developing transformative ophthalmic treatments to improve the sight and lives of patients, today announced that it has closed an oversubscribed US$57 million Series C financing round co-led by BVCF Management and Hyfinity Investments, along with VI Partners and Wille AG joining the existing investors, Bay City Capital, Brunnur Ventures, EarlyBird, funds managed by Tekla Capital Management, Pivotal bioVenture Partners, Nan Fung Life Sciences, Novartis Venture Fund, Silfurberg among other existing investors.
Concurrently, Vanessa Huang, General Partner at BVCF Management, and Dr. Sylvia He, Managing Partner at Hyfinity Investments are joining the Board of Directors while Dr. David Weber and Dr. Thorsteinn Loftsson are stepping down.
This financing will accelerate the strategy to deliver key goals in the near term to drive shareholder value and bring transformative therapies to patients.
“We are entering an exciting new phase of our journey as we advance towards late-stage development and prepare the organization to successfully bring novel therapies to millions of patients worldwide. We feel fortunate to be welcoming such high caliber and diversified new investors and are delighted with the continued support of our existing investors – the quality and breadth of our shareholder base is testament to the exceptional science, groundbreaking development, and the multiple opportunities we have to transform positively patients’ lives globally. Their support and involvement will be crucial for Oculis as we continue to build a global ophthalmology company with a footprint in key markets,” said CEO, Dr. Riad Sherif.
Dr. Zhi Yang, Managing Partner at BVCF Management, added: “Oculis’ innovative science and transformative topical approach to address sight-threatening diseases have the potential to significantly extend the reach of such therapies to larger numbers of patients, improving accessibility and compliance and ultimately clinical outcomes. This unrivaled potential, the strength of the international team at Oculis, and growing unmet medical needs in major key markets around the world are the key factors behind the decision by BVCF and our fellow investors to participate in this new financing round. Together, we look forward to Oculis’ exciting journey ahead.”
About Oculis
Headquartered in Lausanne, Switzerland with global operations in Europe and the U.S., Oculis is a biopharmaceutical company focused on developing transformative innovative ophthalmic treatments to improve the sight and lives of patients. Oculis has a robust and expansive development portfolio including late-stage novel topical (eye drop) treatments, which are non-invasive and represent an unprecedented technical advance for patients with retinal edema and front-of-the-eye diseases. In addition, Oculis’ formulation discovery and innovation capabilities enable the development of a pipeline of topical drugs targeting sight-threatening eye diseases that affect both the anterior and posterior segments of the eye.
For more, visit www.oculis.com
About BVCF Management
BVCF Management, Ltd. is a healthcare investment company that launches and manages funds which invest in global growth-stage healthcare companies with a China focus. BVCF actively assists business owners and entrepreneurs to build their companies into world-class businesses. To date, BVCF has raised five funds. It is headquartered in Shanghai, China with offices in Beijing and Hong Kong SAR.
For more, visit www.bvcf.com
About Hyfinity Investments
Hyfinity Investments is devoted to advancing global innovation targeting high unmet needs and bringing in the rich clinical resources in China. Hyfinity Investments is led by senior partners from top-tier investment institutions in China, with years of experience in healthcare investment, local operation, and overseas licensing. Its mission is to foster industry leaders through converging resources globally.
For more, please visit www.hyfinityfund.com
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
